A Pilot Proof of Concept Single-Center Study of the Use of Oritavancin in Systemic Staphylococcus aureus Infections in Patients with Opioid Use Disorder
Recruiting
99 years or below
All
Phase
4
15 participants needed
1 Location
Brief description of study
The study participants will be in the study for approximately 2 months including the screening, intervention phase and the 6 weeks of follow-up time
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Staphylococcus Aureus Bacteremia | Staphylococcus Aureus Endocarditis
-
Age: 99 years or below
-
Gender: All
Updated on
19 Feb 2024.
Study ID: 831334